If the trial design were up to me, I would try to show non-inferiority to on-label Eylea treatment rather than superiority to a patently substandard regimen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.